FUTURE STRIDES ARCOLAB History

2002

-Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd.

-Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route.

-Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act.

-Incorporates ''Strides Africa Ltd'' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary.

-Board decides to change the name of the company to ''Strides Arcolab (FA)'' to reflect the change in the business focus and operations.

2003

-Nominates Mr Francis Pinto as the Director on the Board of the company.

-Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems.

-Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products.

-Changes in the Management:
Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO.

-Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company.

-Strides inks MoU with Ribbon SRL for Cephalosporin

2004

-Major Fire occurs in Private Custom Bonded warehouse in Mexico

-Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme''''. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job.

2005

- Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets.

-Strides Arcolab enters into an agreement for private placement issue

- Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs

-Strides acquires sterile manufacturing facility in Poland

2007

- Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb''s Sustiva, which helps in preventing the HIV virus from reproduction.
- Strides Arcolab receives 2 more NDA approvals from US-FDA.

2008

- Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials.

2010

- Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company.

2011

-Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite

-Strides announces First European Approval for Oncology Product

-Strides Arcolab receives US FDA Nod to Commercialize First Liquid

-StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited

-Strides Arcolab joins the Malaysian Bio-xcell Ecosystem

2012

-Strides Arcolab Announces US FDA approval for its ''Brazilian Sterile

-Strides Arcolab receives US FDA approval for Methotrexate Injection

-Strides Arcolab Announces Health Canada Approval For Tobramycin Injection

-Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz

-Strides collaborates with Gilead Sciences

2013
-Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet.
- Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility.
- Strides announces WHO pre-qualification for Artemether + Lumifantrine .
-StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology.
-Strides Arcolab - Re-branding Biotech Business as ''''Stelis''''.
-Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market.

2014
-- Medicines for Malaria Venture announces collaborations with Cipla and Strides.
-Strides Arcolab makes strategic investment in Oncobiologics Inc., USA.
- Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries.
-Strides Arcolab receives US FDA approval for Buspirone Tablets.
-Strides Arcolab receives US FDA approval for Calcitriol Softgel.
-Strides Arcolab acquires ''Raricap'' and India Branded Generic Business of Bafna.
-Strides Arcolab to acquire Shasun Pharma in all stock deal.

2015
-Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company''s Public Relations Agenc
-Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc,
-Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso"
-Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350
-Strides Arcolab gets USFDA nod for HIV treatment drug
-Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company.
-Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia.
-Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy
-Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited"

2016
-Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson".
-Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy".
-"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia".
-"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya".
-"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet".
- "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore".

CIN: U67190WB2003PTC096617. Trading in Commodities is done through our Group Company Dynamic Commodities Pvt. Ltd. The company is also engaged in Proprietory Trading apart from Client Business.
“2019 © COPYRIGHT DYNAMIC EQUITIES PVT. LTD.”

Disclaimer: There is no guarantee of profits or no exceptions from losses. The investment advice provided are solely the personal views of the research team. You are advised to rely on your own judgment while making investment / Trading decisions. Past performance is not an indicator of future returns. Investment is subject to market risks. You should read and understand the Risk Disclosure Documents before trading/Investing.

Disclosure: We, Dynamic Equities Private Limited are also engaged in Proprietory Trading apart from Client Business. In case of any complaints/grievances, clients may write to us at compliance@dynamiclevels.com

  • Download our Mobile App
  • Available on Google Play
  • Available on App Store
  • RSS